Endothelin Receptors

BQ-3020 is a selective endothelin receptor (ETB receptor) agonist known for its ability to displace [125I] ET-1 binding at ETB receptors, exhibiting an IC50 of 0.2 nM. This compound induces vasoconstriction in the rabbit pulmonary artery and promotes relaxation of the pig urinary bladder neck. BQ-3020 is valuable for research in cardiovascular diseases, providing insights into endothelin signaling pathways and their physiological implications.

Daglutril targets the endothelin receptor, exhibiting the ability to modulate cytokine-induced endothelin-1 production in astrocytes. Its inhibitory effects on endothelin-1 generation make it a valuable research tool for screening compounds that regulate this peptide's synthesis in glial cells. This compound is particularly relevant for studies investigating the role of endothelin-1 in neuroinflammation and related neurological disorders.

TAK 044 is an antagonist of the Endothelin Receptor, exhibiting potent inhibitory effects on endothelin-induced pathological changes in various animal models. This compound is valuable for exploring the role of endothelin in diseases such as acute myocardial infarction, acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage. Researchers can leverage TAK 044 to investigate therapeutic strategies targeting endothelin-related conditions.

PD 156252 is a highly potent endothelin antagonist, primarily targeting the ETA and ETB receptor subtypes. It exhibits enhanced binding affinity with IC50 values of 1.0 nM for rabbit ETA receptors and 40 nM for rat ETB receptors. This compound is valuable for research applications focusing on the endothelin system, cardiovascular studies, and investigations into related pathophysiological conditions.

ACT-373898 is the inactive carboxylic acid metabolite of Macitentan, a non-peptide dual antagonist of ETA and ETB endothelin receptors. This compound serves as a valuable reference for studies examining the pharmacokinetics and metabolic pathways of Macitentan. Its characterization is essential for understanding the therapeutic efficacy and safety profiles associated with endothelin receptor modulation in cardiovascular research.

TA-0201 is a competitive, non-peptide antagonist targeting endothelin receptors. It effectively inhibits the binding of [125I]ET-1 to cloned human ETA and ETB receptors, demonstrating Ki values of 15 pM and 41 nM, respectively. TA-0201 further reduces the pressor response induced by exogenous big ET-1, making it a valuable tool for studies aimed at understanding endothelin-mediated pathways and potential therapeutic interventions in cardiovascular research.

Edonentan is a potent endothelin receptor antagonist, specifically targeting the ETA receptor with an affinity (Ki) of 10 pM. This compound demonstrates metabolic stability and favorable pharmacokinetic properties in rat models. Edonentan effectively modulates the endothelin system by inhibiting the hypertensive response induced by big endothelin, making it a valuable tool for research in cardiovascular and renal disease studies.

PD 145065 is a highly potent non-selective endothelin receptor antagonist, demonstrating an IC50 value of 4 nM for the ETA receptor in rabbit renal artery vascular smooth muscle cells. This compound effectively inhibits endothelin signaling, making it useful for investigating the role of endothelin in cardiovascular biology and related disorders. PD 145065 is a valuable tool for researchers studying vascular physiology and potential therapeutic interventions targeting endothelial dysfunction.

L-749329 is a potent antagonist of the endothelin receptor subtypes ETA and ETB, exhibiting binding affinities (Kis) of 0.062 nM and 2.25 nM, respectively. This compound effectively inhibits endothelin-1 (ET-1)-stimulated signaling pathways, making it a valuable tool for studying the role of endothelin receptors in pathophysiological conditions. L-749329 is applicable in research focused on cardiovascular diseases, vascular biology, and related fields where endothelin signaling is implicated.

Atrasentan sodium is a selective endothelin receptor antagonist, exhibiting an IC50 of 0.0551 nM for the ETA receptor. This compound demonstrates significant biological activity by inhibiting endothelin-1-mediated vasoconstriction and fibrosis. Atrasentan sodium is primarily utilized in research applications related to cardiovascular diseases, pulmonary hypertension, and kidney injury, making it valuable for studies on endothelin signaling pathways and potential therapeutic interventions.

WS009B is a selective endothelin receptor antagonist, exhibiting IC50 values of 0.67 μM for ET-1 and 0.8 μM for ET-2. This compound is useful for research into cardiovascular diseases, as it modulates the endothelin signaling pathway, which plays a critical role in vascular homeostasis and pathological conditions. WS009B's antagonistic properties make it a valuable tool for elucidating the mechanisms underlying endothelin-mediated physiological and pathological processes.

ATZ-1993 is a potent orally active nonpeptide antagonist of endothelin receptor subtype A and B, exhibiting pKi values of 8.69 and 7.20, respectively. This compound demonstrates significant potential in the study of intimal hyperplasia following balloon denudation of the carotid artery. ATZ-1993 can serve as a valuable tool in cardiovascular research, aiding in the exploration of vascular remodeling and related pathophysiological processes.

BMS 182874 hydrochloride is a highly selective antagonist of the endothelin ETA receptor, exhibiting an IC50 value of 0.150 μM and a Ki of 0.055 μM. This compound demonstrates efficacy in reducing arterial pressure in rat models of hypertension induced by deoxycorticosterone acetate. BMS 182874 hydrochloride is suitable for research applications focused on cardiovascular diseases and endothelin receptor modulation.

IRL 1038 is a selective antagonist for the endothelin B receptor, with a binding affinity characterized by a Ki range of 6-11 nM. This compound effectively inhibits the actions of endothelin-1, crucial for studies investigating vascular function, cardiovascular diseases, and related physiological processes. Its application is valuable in elucidating the role of endothelin signaling in various pathophysiological conditions.

IRL-3630 is a selective antagonist of the ETA and ETB receptors, exhibiting binding affinities with Ki values of 1.9 nM and 1.2 nM, respectively. This compound is instrumental in studying the role of endothelin receptors in various physiological and pathological processes. Its applications include cardiovascular research, pulmonary hypertension studies, and investigations into renal function.

SB-209670 is a highly potent non-peptide antagonist of the endothelin (ET) receptor, exhibiting subnanomolar affinity with Ki values of 0.2 nM for ETA and 18 nM for ETB. This compound effectively inhibits the binding of 125I-labeled ET-1 to both human ET receptor subtypes, making it a valuable tool in cardiovascular and neurological research. SB-209670 demonstrates significant biological activity by reducing blood pressure in hypertensive models, offering neuroprotective effects against ischemia-induced neuronal degeneration, and inhibiting neointima formation following carotid artery balloon angioplasty in rats.

WS009A is a potent antagonist of endothelin receptors, exhibiting IC50 values of 5.8 µM and 6.9 µM for the ET-1 and ET-2 receptors, respectively. This compound is valuable for investigating the role of endothelin signaling in cardiovascular diseases and potential therapeutic applications. Its effective inhibition of endothelin receptors makes WS009A a useful tool for researchers studying vascular dysfunction and related pathophysiological conditions.

Desmethyl Bosentan is an active metabolite of the endothelin receptor antagonist bosentan. It functions primarily by activating the pregnane X receptor (PXR), as demonstrated in CV-1 monkey kidney cells expressing the human receptor in a reporter assay at a concentration of 25 μM. This compound is valuable for studying drug metabolism and the regulatory pathways involved in pharmacokinetics and toxicology research.

Hydroxy bosentan is an endogenous metabolite derived from Bosentan, primarily processed by the cytochrome P450 system in the liver. This compound retains 10%-20% of Bosentan's pharmacological activity, serving as a significant contributor to the overall therapeutic effects of the parent compound. Hydroxy bosentan is useful in research focused on metabolic pathways and the pharmacokinetics of endothelin receptor antagonists.

(Rac)-Ambrisentan-d5 is a deuterium-labeled form of (Rac)-Ambrisentan, functioning primarily as a selective endothelin receptor antagonist. Its key biological activity includes inhibition of endothelin-1, a peptide known to play a crucial role in vasoconstriction and blood pressure regulation. This stable isotope is particularly useful in pharmacokinetic studies, allowing for precise tracking of drug metabolism and distribution in biological systems.

Sulfisoxazole is an orally active endothelin receptor antagonist primarily targeting endothelin receptor A (IC50 = 0.60 μM) and endothelin receptor B (IC50 = 22 μM). This sulfonamide antibacterial agent boasts an oxazole substituent, enhancing its pharmacological profile. Sulfisoxazole is notably effective in inhibiting breast cancer exosome release through its action on endothelin receptor A, making it relevant for cancer research and studies focused on exosome biology.